Effectiveness of Manual Terminal Cleaning Varies on High-Touch Surfaces Near the Operative Field.

Background: Periprosthetic joint infection may result from pathogen to patient transmission within the environment. The purpose of this study is to evaluate the contamination level of selected high-touch surfaces in the operating room (OR) using a blacklight fluorescent marking system after a manual terminal clean.

Methods: Prior to the manual terminal clean, 16 high-touch surfaces were marked using a blacklight fluorescent gel.

Correction: Stuckey et al. Why the Tsirelson Bound? Bub's Question and Fuchs' Desideratum. 2019, , 692.

The authors wish to make the following correction to this paper [...

No Preferred Reference Frame at the Foundation of Quantum Mechanics.

Quantum information theorists have created axiomatic reconstructions of quantum mechanics (QM) that are very successful at identifying precisely what distinguishes quantum probability theory from classical and more general probability theories in terms of information-theoretic principles. Herein, we show how one such principle, Information Invariance and Continuity, at the foundation of those axiomatic reconstructions, maps to "no preferred reference frame" (NPRF, aka "the relativity principle") as it pertains to the invariant measurement of Planck's constant for Stern-Gerlach (SG) spin measurements. This is in exact analogy to the relativity principle as it pertains to the invariant measurement of the speed of light at the foundation of special relativity (SR).

Beyond Causal Explanation: Einstein's Principle Not Reichenbach's.

Our account provides a local, realist and fully non-causal principle explanation for EPR correlations, contextuality, no-signalling, and the Tsirelson bound. Indeed, the account herein is fully consistent with the causal structure of Minkowski spacetime. We argue that retrocausal accounts of quantum mechanics are problematic precisely because they do not fully transcend the assumption that causal or constructive explanation must always be fundamental.

Re-Thinking the World with Neutral Monism:Removing the Boundaries Between Mind, Matter, and Spacetime.

Herein we are not interested in merely using dynamical systems theory, graph theory, information theory, etc., to model the relationship between brain dynamics and networks, and various states and degrees of conscious processes. We are interested in the question of how phenomenal conscious experience and fundamental physics are most deeply related.

Answering Mermin's challenge with conservation per no preferred reference frame.

In 1981, Mermin published a now famous paper titled, "Bringing home the atomic world: Quantum mysteries for anybody" that Feynman called, "One of the most beautiful papers in physics that I know." Therein, he presented the "Mermin device" that illustrates the conundrum of quantum entanglement per the Bell spin states for the "general reader." He then challenged the "physicist reader" to explain the way the device works "in terms meaningful to a general reader struggling with the dilemma raised by the device.

Why the Tsirelson Bound? Bub's Question and Fuchs' Desideratum.

To answer Wheeler's question "Why the quantum?" via quantum information theory according to Bub, one must explain both why the world is quantum rather than classical and why the world is quantum rather than superquantum, i.e., "Why the Tsirelson bound?" We show that the quantum correlations and quantum states corresponding to the Bell basis states, which uniquely produce the Tsirelson bound for the Clauser-Horne-Shimony-Holt (CHSH) quantity, can be derived from conservation per no preferred reference frame (NPRF).

Phase II evaluation of amonafide in advanced sarcoma: a Southwest Oncology Group study.

Soft tissue sarcomas are generally resistant to most chemotherapeutic agents, and individuals with advanced disease have a poor prognosis. We evaluated amonafide, a new drug that has significant activity against several tumor cell lines, to determine its activity against sarcomas. Amonafide was administered to 18 patients with advanced soft tissue sarcoma (16 of whom had received prior chemotherapy) at a dose of 300 mg/m2 over 60 min daily for 5 days.

Mitoxantrone (dihydroxyanthracenedione) in acute leukemia. An evaluation of two treatment schedules by the Southwest Oncology Group.

Fifty-eight evaluable patients with acute leukemia were treated with Mitoxantrone (DHAD) according to two schedules: 14 mg/M2 as a single I.V. pulse dose administered three-week intervals, and 4 mg/M2/day for five days every three weeks.

Phase II evaluation of didemnin B in advanced adenocarcinoma of the kidney. A Southwest Oncology Group study.

The Southwest Oncology Group studied the response rate and toxicity of didemnin B (3.47 mg/m2 i.v.

A phase II randomized study comparing sequential and combined intraarterial cisplatin and radiation therapy in primary brain tumors. A Southwest Oncology Group study.

The Southwest Oncology Group conducted a trial of intra-arterial cisplatin (150 mg intravenously every 21 days for 2 doses) administered concomitant with or before radiation therapy. Because of technical difficulties cannulating the artery, 27 of 33 eligible patients were able to receive the cisplatin by arterial injection. Five patients died before completion of the study, and 11 patients in each treatment arm were evaluable for response.

Unbound immunoglobulins are a major source of error in the quantitation of platelet surface-bound immunoglobulin levels.

Analysis of assays for the determination of platelet-associated immunoglobulins (PAIgs) has led to disagreement over the amount of surface-bound Igs in both normal controls and patients with elevated platelet Ig levels. By the use of radiolabeled platelets and platelet counts, it was demonstrated that more than 10(8) platelets are disrupted after each centrifugation during platelet isolation procedures, releasing intraplatelet contents into the fluid phase of resuspended platelets in buffer. It was shown that suspensions of whole washed platelets contain a significant, but generally overlooked, amount of unbound Igs that have been liberated from platelets disrupted during processing.

A weekly cisplatin-based induction regimen for extensive non-small cell lung cancer. A Southwest Oncology Group study.

The purpose of this Phase II pilot study was to determine whether a dose-intensive regimen of weekly cisplatin combined with other active non-cross-resistant agents would improve the response rate and survival time of patients with extensive non-small cell lung cancer. Patients received cisplatin (50 mg/m2/wk) on days 1, 8, 15, 22, 36, 43, 50, and 57 combined with mitomycin C (8 mg/m2) on days 1 and 36, vinblastine (3 mg/m2) on days 8 and 43, and 5-fluorouracil (5-FU) (1 g/m2) by continuous infusion over 24 hours on days 15 and 50. Responding patients received consolidation therapy with cisplatin and etoposide (VP-16).

Clinical cancer research in Louisiana.

The Ochsner Medical Institutions of New Orleans and Baton Rouge, the Louisiana State Medical Centers in New Orleans and Shreveport, and the Tulane Medical Center of New Orleans are all actively involved in the conduct of National Cancer Institute approved and sponsored clinical trials. Through the efforts of investigators at these institutions, avant-garde, state-of-the-art cancer clinical trials are being made available to the citizens of the state of Louisiana.

Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group Study.

Small cell lung cancer patients who failed primary systemic therapy or who failed after response were randomly assigned to salvage treatment with etoposide (VP-16) and cisplatin (CDDP) or bis-chloro-ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide (BTOC). Good risk patients were those who had tolerated prior chemotherapy well, those who had not had prior radiation therapy, and those who were 65 years of age or younger. Patients with a history of poor tolerance, prior radiation therapy, or those who were older than 65 years of age were classified as poor risk.

Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III, Southwest Oncology Group Study (7613).

The term soft tissue sarcoma refers to a large variety of malignant tumors arising in extraskeletal connective tissues that connect, support, and surround discrete anatomic structures. All visceral organs also contain a connective stroma that can undergo malignant transformation. Because of the histological similarities of this group of tumors and their relative rarity, treatment prescriptions for patients that have disseminated disease are most often uniform.

Combined therapies for squamous-cell carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG-8037).

Conservative treatment of esophageal cancer with radiation therapy has afforded few long-term survivors. In order to improve outcome, patients with locoregional disease were treated using a combined modality approach. Patients were treated with chemotherapy consisting of a 96-hour continuous infusion of 5-fluorouracil (5-FU), 1,000 mg/m2/d, days 1 to 4 and days 29 to 32; cisplatin 75 mg/m2, day 1 and 29; and radiation 3,000 rad, days 1 to 19.

Mechanisms contributing to the anemia associated with a localized solid tumor.

The anemia associated with a localized solid tumor is a chronic hypoproliferative process referred to as the anemia of chronic disease. Several mechanisms responsible for this anemia have been proposed. A defect in iron reutilization was well accepted until challenged by a report in 1977.

Lung cancer following treatment for lymphoma.

Six patients with lung carcinoma from a group of 206 treated for non-Hodgkin's lymphoma and 82 with Hodgkin's disease are described. Review of the literature shows that an increased risk of solid tumors following treatment for lymphoma has not been conclusively demonstrated. However, some series have reported a relative risk two to three times normal.

Hemoglobin production in human bone marrow cultures is inhibited by lyophilized coagulation factor concentrates.

Transfusion of blood products may be followed by viral hepatitis and aplastic anemia despite improved techniques for prevention. In view of the need for intensive therapy of hemophilia with blood products, the authors investigated the capacity of these concentrates to influence cultures of human bone marrow cells. Factor VIII concentrates contained a heat-stable dialyzable substance(s) that drastically impaired 59Fe incorporation in normal human bone marrow.

Salvage treatment of unfavorable non-Hodgkin's lymphoma with cisplatin, amsacrine, and mitoguazone: a Southwest Oncology Group Pilot Study.

We tested the combination of cisplatin, amsacrine, and mitoguazone as salvage treatment for patients with advanced unfavorable non-Hodgkin's lymphomas. An objective response rate of 43% was noted in 30 evaluable patients, but all responses were partial and the median duration of response was only 2 months. Toxicity included life-threatening and fatal leukopenia and severe gastrointestinal intolerance.

Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region: a Southwest Oncology Group Study.

One hundred eligible patients with inoperable, locally advanced or metastatic squamous cell carcinoma of the head and neck region following prior therapy were randomized to receive im methotrexate (50 patients) or iv cisplatin (50 patients). Methotrexate produced a complete plus partial response rate of 16.0% and cisplatin produced a partial response rate of 8.